On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested price negotiations between drugmakers and the administration were ongoing, t he announcement sent Novo Nordisk and Eli Lilly stocks tumbling . For patients who’ve been priced out, that number sounded like relief.

I got three texts within an hour: “Does this mean we won’t need the research suppliers anymore?” “Can we go back to real pharmacies?” “Dr. Dothée, is this real?” That’s what my friends call me.

I’m not a doctor — I’m just the person everyone texts when the rules change again. Most of them aren’t using compounding pharmacies anymore — those dried up when the Food and Drug Administration cracked down. Like me, the

See Full Page